Table 3 Grade 3 and 4 toxicity (adverse events considered at least possibly related to everolimus) was observed in 68% (52/77) of patients
From: A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Toxicity | Grade | Total (%) | |
|---|---|---|---|
3 | 4 | ||
General | |||
Fatigue | 6 | 0 | 6 (8) |
Mouth sores (mucositis) | 2 | 0 | 2 (3) |
Anorexia | 1 | 0 | 1 (1) |
Fever | 1 | 0 | 1 (1) |
Dehydration | 1 | 0 | 1 (1) |
Hypersensitivity | 0 | 1 | 1 (1) |
Edema | 1 | 0 | 1 (1) |
Hematologic | |||
Anemia | 10 | 1 | 11 (14) |
Neutropenia | 12 | 2 | 14 (18) |
Thrombocytopenia | 17 | 12 | 29 (38) |
Metabolic | |||
Hyperglycemia | 6 | 0 | 6 (8) |
Hypertriglyceridemia | 1 | 1 | 2 (3) |
Hypercholesterolemia | 1 | 0 | 1 (1) |
Hyponatremia | 1 | 0 | 1 (1) |
Hypokalemia | 0 | 1 | 1 (1) |
Tumor lysis syndrome | 1 | 0 | 1 (1) |
Renal failure | 0 | 1 | 1 (1) |
Hepatic | |||
Aspartate aminotransferase | 1 | 0 | 1 (1) |
Infection | |||
Respiratory | 3 | 0 | 3 (4) |
Skin | 2 | 0 | 2 (3) |
Urinary tract | 1 | 0 | 1 (1) |
Perianal | 1 | 0 | 1 (1) |
Pulmonary | |||
Cough | 1 | 0 | 1 (1) |
Hypoxia | 1 | 0 | 1 (1) |
Dyspnea | 1 | 0 | 1 (1) |
Pneumonitis | 1 | 0 | 1 (1) |
